Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: Comparative genotypic and phenotypic data

被引:31
作者
Fleury, HJ [1 ]
Toni, T
Lan, NTH
Hung, PV
Deshpande, A
Recordon-Pinson, P
Boucher, S
Lazaro, E
Jauvin, V
Lavignolle-Aurillac, V
Lebel-Binay, S
Cheret, A
Masquelier, B
机构
[1] Univ Bordeaux 2, UPRES EA 2968, Virol Lab, F-33076 Bordeaux, France
[2] CIRBA, Abidjan, Cote Ivoire
[3] Ctr Prevent Med, Ho Chi Minh, Vietnam
[4] Grant Med Coll & Sir JJ Hosp, Bombay, Maharashtra, India
[5] INSERM, U 593, Bordeaux, France
[6] VIRalliance, Paris, France
关键词
D O I
10.1089/aid.2006.22.357
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Non-B HIV-1 viruses are predominant in developing countries where access to antiretroviral drugs ( ARVs) is progressively being intensified. It is important to obtain more data on the susceptibility of these viruses to available ARVs. CRF01_AE, CRF02_AG, and subtype C strains of HIV-1 obtained from untreated patients from Vietnam, Cote d'Ivoire, and India were analyzed for their in vitro susceptibility to NRTIs, NNRTIs, PIs, and an entry inhibitor (T-20) using a recombinant viral assay (PHENOSCRIPT). The corresponding viruses, which had been previously sequenced in reverse transcriptase (RT), protease ( prot), plus envelope (env) C2/ V3 genes and had therefore been fully characterized, were further sequenced in env HR1 + HR2 regions. CRF01_AE isolates are sensitive to NRTIs and NNRTIs with the exception of one isolate that exhibits a decreased susceptibility to NNRTIs associated with a I135T substitution in RT. CRF02_AG and subtype C viruses are sensitive to NRTIs and NNRTIs but some CRF02_AG isolates tend to be resistant to abacavir, potentially related to associated substitutions of RT at positions 123 (D123N) plus 135 (I135V). Whereas all but one CRF01_AE isolates are fully susceptible to PIs, some CRF02_AG and, more frequently, some subtype C isolates are resistant to atazanavir. The role of substitutions in prot at positions of secondary resistance mutations 20, 36, 63, and 82 is raised with a potentially crucial role of the V82I substitution. Finally, all viruses tested, regardless of the CRF or subtype, are fully susceptible to T-20.
引用
收藏
页码:357 / 366
页数:10
相关论文
共 29 条
[1]  
Balotta C, 2001, J ACQ IMMUN DEF SYND, V27, P499, DOI 10.1097/00126334-200108150-00012
[2]   Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion [J].
Brodine, SK ;
Shaffer, RA ;
Starkey, MJ ;
Tasker, SA ;
Gilcrest, JL ;
Louder, MK ;
Barile, A ;
VanCott, TC ;
Vahey, MT ;
McCutchan, FE ;
Birx, DL ;
Richman, DD ;
Mascola, JR .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (07) :502-+
[3]   Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites [J].
Brown, AJL ;
Precious, HM ;
Whitcomb, JM ;
Wong, JK ;
Quigg, M ;
Huang, W ;
Daar, ES ;
D'Aquila, RT ;
Keiser, PH ;
Connick, E ;
Hellmann, NS ;
Petropoulos, CJ ;
Richman, DD ;
Little, SJ .
JOURNAL OF VIROLOGY, 2000, 74 (22) :10269-10273
[4]   Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom [J].
Cane, PA ;
de Ruiter, A ;
Rice, P ;
Wiselka, M ;
Fox, R ;
Pillay, D .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (07) :2652-2654
[5]   Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20 [J].
Cilliers, T ;
Patience, T ;
Pillay, C ;
Papathanasopoulos, M ;
Morris, L .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2004, 20 (05) :477-482
[6]   HIV-1 diversity in France, 1996-1998 [J].
Couturier, E ;
Damond, F ;
Roques, P ;
Fleury, H ;
Barin, F ;
Brunet, JB ;
Brun-Vézinet, F ;
Simon, F .
AIDS, 2000, 14 (03) :289-296
[7]  
Deshpande A, 2004, AIDS RES HUM RETROV, V20, P1032, DOI 10.1089/aid.2004.20.1032
[8]   HIV type 1 diversity in France, 1999-2001: Molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs [J].
Fleury, H ;
Recordon-Pinson, P ;
Caumont, A ;
Faure, M ;
Roques, P ;
Plantier, JC ;
Couturier, E ;
Dormont, D ;
Masquelier, B ;
Simon, F .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2003, 19 (01) :41-47
[9]   Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients [J].
Frater, AJ ;
Beardall, A ;
Ariyoshi, K ;
Churchill, D ;
Galpin, S ;
Clarke, JR ;
Weber, JN ;
McClure, MO .
AIDS, 2001, 15 (12) :1493-1502
[10]   Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC [J].
Girouard, M ;
Diallo, K ;
Marchand, B ;
McCormick, S ;
Götte, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (36) :34403-34410